Additionally, circulatory IL-17A concentration substantially raised with the progression of the disease (advanced vs. early MASLD, p=0.0007, Figure 3C, Table 2). The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatotic liver disease.